Amendments to the Claims

This listing of claims will replace all prior versions, and listings of claims in the application.

1. (currently amended) A compound having ~~one of~~ the Formulae V ~~and VI~~:



(V)



~~(VI)~~

or a pharmaceutically acceptable salt or prodrug thereof, wherein:

Ar_3 is optionally substituted aryl or optionally substituted heteroaryl;

R_1 and R_2 are independently hydrogen, alkyl or cycloalkyl;

R_3-R_{10} are independently hydrogen, halo, haloalkyl, aryl, fused aryl, carbocyclic, a heterocyclic group, a heteroaryl group, alkyl, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl, nitro, amino, cyano, acylamino, hydroxy, thiol, sulfonyl,

phosphonyl, acyloxy, azido, alkoxy, aryloxy, heteroaryloxy, arylalkoxy, heteroarylalkoxy, haloalkoxy, carboxy, carbonylamido or alkylthiol, each of which is optionally substituted;

with the proviso that when ~~said compound is of Formula V and~~ Ar_3 is unsubstituted phenyl then each of R_3-R_7 is other than NH_2, $NHCH_3$, NO_2, Cl or CF_3.

2. (previously presented) The compound of claim 1, wherein R_1 and R_2 are hydrogen.

3. (previously presented) The compound of claim 1, wherein at least one of R_3-R_7 is other than hydrogen.

4. (previously presented) The compound of claim 1, wherein Ar_3 is optionally substituted aryl.

5. (previously presented) The compound of claim 4, wherein Ar_3 is optionally substituted phenyl.

6. (previously presented) The compound of claim 1, wherein Ar_3 is optionally substituted heteroaryl.

7. (canceled).

8. (currently amended). The compound of ~~claim 7~~ claim 1, wherein said compound is selected from the group consisting of:

N'-(2-Phenoxypyridine-3-carbonyl)-4-nitrobenzhydrazide;

N'-(2-Phenoxypyridine-3-carbonyl)-2-amino-5-nitrobenzhydrazide;

N'-[2-(4-Methylphenoxy)pyridine-3-carbonyl]-2-hydroxy-benzhydrazide;

N'-(2-Phenoxypyridine-3-carbonyl)-3-trifluoromethyl)benzhydrazide;

N'-[2-(4-Methylphenoxy)pyridine-3-carbonyl]-3-(trifluoromethyl)benzhydrazide;

N'-(2-Phenoxypyridine-3-carbonyl)-3-hydroxybenzhydrazide;

N'-(2-Phenoxypyridine-3-carbonyl)-3-aminobenzhydrazide;

N'-(2-Phenoxypyridine-3-carbonyl)-4-(trifluoromethyl)benzhydrazide;

N'-(2-Phenoxypyridine-3-carbonyl)-4-hydroxybenzhydrazide;

N'-(2-Phenoxypyridine-3-carbonyl)-2-hydroxybenzhydrazide;

N'-(2-Phenoxypyridine-3-carbonyl)-2-(trifluoromethyl)benzhydrazide;

N'-(2-Phenoxypyridine-3-carbonyl)-3-fluorobenzhydrazide;

N'-(2-Phenoxypyridine-3-carbonyl)-3-nitrobenzhydrazide; and

N'-(2-Phenoxypyridine-3-carbonyl)-2-fluorobenzhydrazide;

and pharmaceutically acceptable salts and prodrugs thereof.

9.-10. (canceled).

11. (currently amended) A compound selected from the group consisting of:

N'-[5-(1-Hexynyl)pyridine-3-carbonyl]-3-(trifluoromethyl)benzhydrazide;

N'-(Pyridine-3-carbonyl)-4-bromobenzhydrazide;

N'-(2-Phenoxypyridine-3-carbonyl)-(N-oxide-pyridine-3-carbonyl)hydrazide;

N'-(2-Phenoxypyridine-3-carbonyl)-(pyridine-3-carbonyl)hydrazide;

N'-[2-(Methylthio)pyridine-3-carbonyl]-3-(trifluoromethyl)benzhydrazide;

2-Phenoxypyridine-3-carboxylic acid (3-pyridylmethylidene)-hydrazide; ~~and~~

2-Phenoxypyridine-3-carboxylic acid (4-pyridylmethylidene)-hydrazide;

2-Chloropyridine-3-carboxylic acid (3-trifluoromethyl-benzylidene)-hydrazide;

2-Anilinopyridine-3-carboxylic acid (3-trifluoromethyl-benzylidene)-hydrazide;

Biphenyl-2-carboxylic acid (3-trifluoromethyl-benzylidene)-hydrazide;

2-(3-Trifluoromethyl-anilino)-pyridine-3-carboxylic acid (3-trifluoromethyl-benzylidene)-hydrazide;

3,4,5-Trimethoxy-benzoic acid (3-trifluoromethyl-benzylidene)-hydrazide;

3,4-Dihydroxy-benzoic acid (3-trifluoromethyl-benzylidene)-hydrazide;

4-(Pyridin-4-yl)-2-(pyridin-2-yl)pyrimidine-5-carboxylic acid (3-trifluoromethyl-benzylidene)-hydrazide;

5-Amino-2-phenoxy-benzoic acid (3-trifluoromethyl-benzylidene)-hydrazide;

2-(Morpholin-4-ylmethyl)-benzoic acid (3-trifluoromethyl-benzylidene)-

hydrazide;

5-Nitro-2-phenoxy-benzoic acid (3-trifluoromethyl-benzylidene)-hydrazide;

2-[1-(6-Chloro-pyridin-2-yl)-1H-[1,2,4]triazol-3ylmethoxy]-benzoic acid (3-trifluoromethyl-benzylidene)-hydrazide;

2-Phenoxybenzoic acid (3-trifluoromethylbenzylidene)-hydrazide; and

2-Phenoxybenzoic acid (2-hydroxybenzylidene)-hydrazide;

and pharmaceutically acceptable salts and prodrugs thereof.

12. (currently amended) A pharmaceutical composition, comprising the compound of claim 1, 8~~, 10~~ or 11, and a pharmaceutically acceptable carrier.

13. (previously presented) The pharmaceutical composition of claim 12, further comprising at least one known cancer chemotherapeutic agent, or a pharmaceutically acceptable salt of said agent.

14. (previously presented) The pharmaceutical composition of claim 13, wherein said known cancer chemotherapeutic agent is selected from the group consisting of busulfan, cis-platin, mitomycin C, carboplatin, colchicine, vinblastine, paclitaxel, docetaxel, camptothecin, topotecan, doxorubicin, etoposide, 5-azacytidine, 5-fluorouracil, methotrexate, 5-fluoro-2'-deoxy-uridine, ara-C, hydroxyurea, thioguanine, melphalan, chlorambucil, cyclophosamide, ifosfamide, vincristine, mitoguazone, epirubicin, aclarubicin, bleomycin, mitoxantrone, elliptinium, fludarabine, octreotide, retinoic acid, tamoxifen, Herceptin®, Rituxan® and alanosine.

15. (currently amended) A method of treating a disorder responsive to the induction of apoptosis in an animal suffering therefrom, comprising administering to an animal in need of such treatment an effective amount of a compound of claim 1. ~~having one of the Formulae I and II:~~



(I)



(II)

~~or a pharmaceutically acceptable salt or prodrug thereof, wherein:~~

~~Ar_1 is optionally substituted pyridyl, optionally substituted pyrimidinyl or optionally substituted phenyl;~~

~~Ar_2 is optionally substituted aryl or optionally substituted heteroaryl; and~~

~~R_1 and R_2 are independently hydrogen, alkyl or cycloalkyl;~~

~~with the proviso that said compound is other than 4-hydroxybenzoic acid (2-hydroxybenzylidene) hydrazide.~~

16. (previously presented) The method of claim 15, wherein said animal is a mammal.

17. (previously presented) The method of claim 15, wherein R_1 and R_2 are hydrogen.

18.-36. (canceled).

37. (currently amended) The method of claim ~~35~~ 15, wherein R_3-R_{10} independently are hydrogen, halogen, methyl, trifluoromethyl, hydroxy, methoxy, NH_2, $NHCH_3$ or $N(CH_3)_2$.

38. (currently amended) The method of claim ~~35~~ 15, wherein Ar_3 is optionally substituted aryl.

39. (currently amended) The method of claim ~~35~~ 15, wherein Ar_3 is optionally substituted phenyl.

40. (currently amended) The method of claim ~~35~~ 15, wherein Ar_3 is optionally substituted heteroaryl.

41. (canceled).

42. (currently amended) The method of claim ~~41~~ 15, wherein said compound is selected from the group consisting of:

N'-(2-Phenoxypyridine-3-carbonyl)-4-nitrobenzhydrazide;
N'-(2-Phenoxypyridine-3-carbonyl)-2-amino-5-nitrobenzhydrazide;
N'-[2-(4-Methylphenoxy)pyridine-3-carbonyl]-2-hydroxy-benzhydrazide;
N'-(2-Phenoxypyridine-3-carbonyl)-3-trifluoromethyl)benzhydrazide;
N'-[2-(4-Methylphenoxy)pyridine-3-carbonyl]-3-(trifluoromethyl)benzhydrazide;
N'-(2-Phenoxypyridine-3-carbonyl)-3-hydroxybenzhydrazide;
N'-(2-Phenoxypyridine-3-carbonyl)-3-aminobenzhydrazide;
N'-(2-Phenoxypyridine-3-carbonyl)-4-(trifluoromethyl)benzhydrazide;
N'-(2-Phenoxypyridine-3-carbonyl)-4-hydroxybenzhydrazide;
N'-(2-Phenoxypyridine-3-carbonyl)-2-hydroxybenzhydrazide;
N'-(2-Phenoxypyridine-3-carbonyl)-2-(trifluoromethyl)benzhydrazide;
N'-(2-Phenoxypyridine-3-carbonyl)-3-fluorobenzhydrazide;
N'-(2-Phenoxypyridine-3-carbonyl)-3-nitrobenzhydrazide; and
N'-(2-Phenoxypyridine-3-carbonyl)-2-fluorobenzhydrazide;
and pharmaceutically acceptable salts and prodrugs thereof.

43.-46 (canceled)

47. (currently amended) A method for treating or preventing cancer comprising administering to an animal in need of such treatment an effective amount of a compound of claim 1. ~~having one of the Formulae I and II:~~



(I)



(II)

~~or a pharmaceutically acceptable salt or prodrug thereof, wherein:~~

~~Ar_1 is optionally substituted pyridyl, optionally substituted pyrimidinyl or optionally substituted phenyl;~~

~~Ar_2 is optionally substituted aryl or optionally substituted heteroaryl; and~~

~~R_1 and R_2 are independently hydrogen, alkyl or cycloalkyl;~~

~~with the proviso that said compound is other than 4-hydroxybenzoic acid (2-hydroxybenzylidene) hydrazide.~~

48. (previously presented) The method of claim 47, wherein said animal is a mammal.

49. (previously presented) The method of claim 47, wherein R_1 and R_2 are hydrogen.

50.-54. (canceled).

55. (previously presented) The method of claim 47, wherein said cancer is selected from the group consisting of Hodgkin's disease, non-Hodgkin's lymphoma, acute lymphocytic leukemia, chronic lymphocytic leukemia, multiple myeloma, neuroblastoma, breast carcinoma, ovarian carcinoma, lung carcinoma, Wilms' tumor, cervical carcinoma, testicular carcinoma, soft-tissue sarcoma, primary macroglobulinemia, bladder carcinoma, chronic granulocytic leukemia, primary brain carcinoma, retinoblastoma, glioma, malignant melanoma, small-cell lung carcinoma, stomach carcinoma, colon carcinoma, malignant pancreatic insulinoma, malignant carcinoid carcinoma, malignant melanoma, choriocarcinoma, mycosis fungoides, head or neck carcinoma, osteogenic sarcoma, pancreatic carcinoma, acute granulocytic leukemia, hairy cell leukemia, neuroblastoma, rhabdomyosarcoma, Kaposi's sarcoma, genitourinary carcinoma, thyroid carcinoma, esophageal carcinoma, malignant hypercalcemia, cervical hyperplasia, renal cell carcinoma, endometrial carcinoma, polycythemia vera, essential thrombocytosis, adrenal cortex carcinoma, skin cancer and prostatic carcinoma.

56. (previously presented) The method of claim 47, wherein said cancer is drug resistant and hormone dependent or independent breast carcinoma.

57.-58. (canceled).

59. (currently amended) A method for treating or preventing drug resistant cancer comprising administering to an animal in need of such treatment an effective amount of a compound of claim 1. ~~having one of the Formulae I and II:~~



(I)



(II)

~~or a pharmaceutically acceptable salt or prodrug thereof, wherein:~~

~~Ar_1 is optionally substituted pyridyl, optionally substituted pyrimidinyl or optionally substituted phenyl;~~

~~Ar_2 is optionally substituted aryl or optionally substituted heteroaryl; and~~

~~R_1 and R_2 are independently hydrogen, alkyl or cycloalkyl.~~

60. (previously presented) The method of claim 59, wherein said animal is a mammal.

61. (previously presented) The method of claim 59, wherein R_1 and R_2 are hydrogen.

62.-66. (canceled).

67. (previously presented) The method of claim 47 or 59, additionally comprising administering at least one known cancer chemotherapeutic agent, or a pharmaceutically acceptable salt of said agent.

68. (previously presented) The method of claim 67, wherein said known cancer therapeutic agent is selected from the group consisting of busulfan, cis-platin, mitomycin C, carboplatin, colchicine, vinblastine, paclitaxel, docetaxel, camptothecin, topotecan, doxorubicin, etoposide, 5-azacytidine, 5-fluorouracil, methotrexate, 5-fluoro-2'-deoxy-

uridine, ara-C, hydroxyurea, thioguanine, melphalan, chlorambucil, cyclophosamide, ifosfamide, vincristine, mitoguazone, epirubicin, aclarubicin, bleomycin, mitoxantrone, elliptinium, fludarabine, octreotide, retinoic acid, tamoxifen, Herceptin® or Rituxan® and alanosine.

69. (previously presented) The method of claim 47 or 59, additionally comprising treating said animal with radiation-therapy.

70. (previously presented) The method of claim 47 or 59, wherein said compound is administered after surgical treatment of said animal for said cancer.

71.-73. (canceled).

74. (previously presented) The method of claim 15, wherein said disorder is an autoimmune disease.

75. (previously presented) The method of claim 15, wherein said disorder is an infectious viral disease.

76. (previously presented) The method of claim 15, wherein said disorder is rheumatoid arthritis.

77. (previously presented) The method of claim 15, wherein said disorder is inflamatory bowel disease.

78. (previously presented) The method of claim 15, wherein said disorder is a skin disease.

79. (previously presented) The method of claim 77, wherein said disorder is psoriasis.